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RNA binding proteins co-localize with small
tau inclusions in tauopathy
Brandon F. Maziuk1, Daniel J. Apicco1, Anna Lourdes Cruz1, Lulu Jiang1, Peter E. A. Ash1,
Edroaldo Lummertz da Rocha2, Cheng Zhang2, Wai Haung Yu3, John Leszyk4, Jose F. Abisambra5, Hu Li2
and Benjamin Wolozin1,6,7*
Abstract
The development of insoluble, intracellular neurofibrillary tangles composed of the microtubule-associated protein
tau is a defining feature of tauopathies, including Alzheimer’s disease (AD). Accumulating evidence suggests that
tau pathology co-localizes with RNA binding proteins (RBPs) that are known markers for stress granules (SGs). Here
we used proteomics to determine how the network of tau binding proteins changes with disease in the rTg4510
mouse, and then followed up with immunohistochemistry to identify RNA binding proteins that co-localize with
tau pathology. The tau interactome networks revealed striking disease-related changes in interactions between tau
and a multiple RBPs, and biochemical fractionation studies demonstrated that many of these proteins including
hnRNPA0, EWSR1, PABP and RPL7 form insoluble aggregates as tau pathology develops. Immunohistochemical
analysis of mouse and human brain tissues suggest a model of evolving pathological interaction, in which RBPs
co-localize with pathological phospho-tau but occur adjacent to larger pathological tau inclusions. We suggest a
model in which tau initially interacts with RBPs in small complexes, but evolves into isolated aggregated inclusions
as tau pathology matures.
Keywords: Alzheimer’s disease, Neurofibrillary tangle, Immunohistochemistry, Mass spectrometry, Protein interactome,
Protein aggregation
Introduction
RNA binding proteins (RBPs) have emerged as major
factors in a number of neurodegenerative disorders, in-
cluding tauopathies [31, 32]. RBPs represent a large class
of proteins responsible for RNA metabolism, regulating
key events including mRNA maturation, trafficking, and
eventual translation. Importantly, many RBPs have been
shown to have strong genetic links to neurodegenerative
disease; for example, mutations in TDP-43, FUS,
hnRNPA1, and ATXN2 have all been shown to cause
amyotrophic lateral sclerosis (ALS), frontotemporal lobar
degeneration (FTLD) and/or spinocerebellar ataxia [24].
Other RBPs have also been implicated in AD, Hunting-
ton’s disease, and Creutzfeldt-Jakob disease [24].
Following these initial discoveries, evidence now suggests
that transient aggregation mediated by low-complexity do-
mains within RBPs is crucial for the involvement of these
proteins in disease. RBPs typically contain a “prion-like”,
low complexity glycine-rich domain in their sequences,
which regulate their self-aggregation [21, 35]. This regu-
lated aggregation is important for RBP function, as many
RBPs regulate the formation of a variety of ribonucleopro-
tein (RNP) granules. Such granules, which include stress
granules (SGs) and P-bodies, are responsible for the transi-
ent recruitment and aggregation of mRNA transcripts for
varying purposes [29, 32]. SGs recruit mRNA into granules
for storage and protection following translational stress,
while P-bodies recruit mRNA for eventual degradation
[29, 32]. Many disease-linked RBPs are proteins in-
volved in the formation and maintenance of SGs.
In particular, recent findings have shown that T-cell
intracellular antigen 1 (TIA1) and other RBPs interact
with hyper-phosphorylated tau and accumulate in tan-
dem with tau pathology in diseases such as Alzheimer’s
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disease (AD) and frontotemporal dementia (FTD) [37, 38].
RBPs also regulate splicing of MAPT exon 10, which pro-
vides an additional mechanism for control of tau aggrega-
tion by determining whether the tau transcript codes for 3
or 4 microtubule repeats [9, 18, 40]. The aggregation of
tau is a major pathological hallmark of these diseases,
where the microtubule associated protein tau becomes
hyperphosphorylated, and mislocalizes in the soma [41].
Once in the soma, tau begins to aggregate, eventually
forming large neurofibrillary tangles and resulting in neu-
rodegeneration. Recently, our lab demonstrated that tau
interacts with TIA1 in SGs, which increases in sarkosyl
insoluble aggregates. The association of tau with TIA1 and
SGs also was shown to promote tau-mediated degener-
ation of primary hippocampal neurons [37]. This pheno-
type can be rescued by TIA1 knockdown in primary
neurons [37]. We proceeded to show that TIA1 reduction
(haploinsufficiency) is also protective in vivo, reducing
neurodegeneration, rescuing cognition and increasing sur-
vival in the PS19 mouse model of tauopathy [1]. These re-
sults point to an essential role for TIA1 and SG biology in
the pathophysiology of tauopathy.
We now present an enhanced view of the interaction of
RBPs in the pathophysiology of tauopathy. We have used
a proteomic approach to identify multiple RBPs that have
significantly altered associations with tau as pathology de-
velops in the rTg4510 mouse model of tauopathy includ-
ing multiple splicing factors. The rTg4510 mouse model
of tauopathy inducibly expresses P301L 4R0N tau under
control of a tetracycline promoter, and when aged in
the absence of doxycycline develop pathology by 4–
5 months [30]. We also present optimized immunohisto-
chemical methods for detecting RBPs in pathological tis-
sues. We combine the optimized immunohistochemical
methods with biochemical methods to validate the
proteomic findings. We identify specific RBPs that asso-
ciate with pathological phospho-tau early in disease and
become increasingly insoluble as disease progresses.
Together our results provide important evidence indi-
cating that RNA binding protein pathologies are a
major feature of tauopathy.
Results
TIA1 colocalizes with phosphorylated tau in tauopathy
Recent work from our laboratory demonstrates that TIA1
and other SG markers colocalize with pathological tau in
Tg4510 and PS19 mouse brains as well as human
post-mortem AD and FTDP-17 brain samples [1, 37, 38].
Immunohistochemical identification of TIA1 inclusions in
pathological samples has proven to be particularly diffi-
cult, with some observing TIA1 inclusions, and others un-
able to observe inclusions [8, 11, 15]. While this could
represent differences in the types of cases examined, we
have also observed TIA1 reactivity to be highly sensitive
to methodological conditions.
To improve reproducibility among laboratories, we set
out to define optimal conditions for TIA1 immunohisto-
chemistry. We began by determining optimal conditions
for fixation of mouse tissue. rTg4510 tissues were
drop-fixed in 4% buffered paraformaldehyde for 24 or
48 h, then transferred to 30% sucrose, incubated at 4 °C
for 48 h, sectioned and subjected to immunohistochem-
istry. Shorter fixation times produced much stronger re-
activity for both TIA1 and NeuN, which is also a RNA
binding protein (Additional file 1: Figure S4). The 24 h
fixation protocol was used for all subsequent experi-
ments using animal tissues. We also optimized condi-
tions to reduce background. Our previous studies used
Sudan black to quench background fluorescence, how-
ever such quenching also has the drawback of reducing
antibody signals [23, 38]. Photobleaching proved to pro-
vide much more effective quenching of autofluorescence
without significant loss of antibody reactivity (Additional
file 1: Figure S5). Application of shorter fixation times
and photobleaching significantly improved the sensitivity
for detecting RBPs in tissue samples.
Next we compared commercially available antibodies
for immunohistochemical reactivity. We observed that the
anti-TIA1 antibody from Abcam (Abcam cat#40693) gave
the strongest results (Fig. 1, Additional file 1: Figure S1).
Using the Abcam antibody, we consistently observed
TIA1 colocalization with CP13 positive phospho-tau in
the rTg4510 and the PS19 mouse models of tauopathy
(Fig. 1a-c). The strength of reactivity varied with lot
number (Fig. 1e), and thus the work in this manuscript
used lot GR151575 (Fig. 1e). Reactivity with antibodies
from other vendors did not work as well as the Abcam
antibodies (Additional file 1: Figure S1). In all cases,
specificity of the TIA1 reactivity was demonstrated by
the absence of anti-TIA1 reactivity observed following
immuno-adsorption or staining of TIA1 knockout brain
tissue (Fig. 1d). These results demonstrate that immu-
nohistochemical reactivity with the Abcam anti-TIA1
antibody is bona-fide TIA1 reactivity.
We proceeded to characterize how the co-localization
of TIA1 and tau varied with the type of tau pathology.
Analysis of patterns of co-localization in 6 month-old
rTg4510 brain tissue demonstrated a distinct correlation
of TIA1 co-localization with the size of CP13-positive
tau inclusions (Fig. 1e, f ). Abundant co-localization was
observed with small CP13 reactive puncta, while little
co-localization was observed with large fibrillar CP13
positive tau inclusions (Fig. 1e). Previous results from
our laboratory indicate that TIA1 selectively interacts with
oligomeric tau [1]. To test whether the small TIA1 react-
ive inclusions contained tau oligomers, we probed the
tissues with the anti-tau oligomer antibody TOC1 [19].
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Strong co-localization was observed between anti-TIA1
and the TOC1 tau oligomer specific antibodies (Fig. 1f,
R = − 0.1617, p = 0.0404). From this we conclude that
TIA1 preferentially associates with small tau inclusions
containing oligomeric tau.
Other RNA binding proteins change in their association to
tau in tauopathy
The association of phosphorylated tau with the stress
granule protein TIA1 raises the possibility that other RBPs
and ribosomal proteins might also interact with tau [1, 25,
26, 37]. To explore the tau interactome, we immunopreci-
pitated (IP) total human tau from 2.5 month old Tg4510
mouse frontal cortex expressing low or high amounts of
human tau protein due to inclusion or exclusion of doxy-
cycline from the mouse chow, respectively; IPs were per-
formed using the Tau13 antibody, which is a high affinity
antibody that selectively recognizes total human tau (inde-
pendent of tau phosphorylation state) [5]. We also did IPs
from MAPT −/− mice to provide negative controls for the
IPs. This design allowed exploration of neurons exposed
to relatively low or high amounts of stress, but preceding
a phase with extensive neurodegeneration. The tau com-
plexes were then analyzed using orbitrap mass spectrom-
etry to identify proteins in the tau interactome (Fig. 2);
any proteins pulled down by the Tau13 antibody from the
MAPT−/− mice were removed from tau interactome ob-
served in the rTg4510 IPs. This analysis identified a large
Fig. 1 TIA1 preferentially colocalizes with phosphorylated tau that is not in NFTs. Immunohistochemical analysis of the stress granule nucleating
protein TIA1 (red) shows colocalization with phosphorylated tau (CP13 antibody against pSer202, green) in rTg4510 (a), PS19 (b) and human AD
tissues (c) with DAPI in blue. d Immunohistochemistry of TIA1 on rTg4510 with and without immunosorbtion using TIA1 peptide, as well as TIA1
staining of TIA1 knockout mouse tissue, also show that the TIA1 antibody used for this analysis is specific for TIA1 and does not have off-target
staining. e Further analysis of TIA1-tau colocalization in rTg4510 tissues indicates that TIA1 primarily has cytoplasmic colocalization with smaller
tau aggregates (white arrow) over larger NFT-like tau aggregates (pink arrow). This is quantified in (f) using Imaris Bitplane software, where
cytoplasmic TIA1 intensity negatively correlates with the size of tau tangles in neurons (R = − 0.1617 with a two tailed p value of 0.0404).
g TIA1 also colocalizes with oligomeric tau stained using the TOC1 antibody specific for oligomeric tau
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number of proteins associated with tau, including RBPs,
translational and ribosomal proteins, cytoskeletal proteins,
chaperones, heat shock proteins and synaptic proteins
(Fig. 2 and Additional file 2: Table S1).
Comparing the tau networks from the induced and
un-induced rTg4510 mice revealed striking changes.
Multiple proteins showed decreased association with
tau in the 2.5 m induced rTg4510 mice. Proteins linked
to RNA metabolism comprised 3 of the top 6 GO an-
notations categories of decreased proteins (Fig. 2a, bot-
tom panel). Interaction of tau with some of these
proteins, including HNRNPA0, HNRNPK, eIF4a, and
RPL11, was validated by immunoprecipitating tau from
6 month old PS19 P301S tau mouse brains; these mice
overexpress mutant P301S tau at 5 times endogenous
levels (Additional file 1: Figure S2). Confirmation is also
provided by comparison to our prior study showing the
requirement of tau for the presence of many proteins in
the TIA1 interactome network [37]. These changes
corresponded to large-scale changes in the interaction
of tau with these particular groups of proteins. For
instance, 65% of proteins in the RBP group showed
decreased association with disease; in contrast, only
16% of proteins in the synaptic and vesicular protein
group showed decreased association with disease
(Fig. 2a).
The groups of proteins whose interaction with tau in-
creased with disease were equally striking. Heat shock
proteins/chaperones and phospho-proteins were 2 of the
3 groups of proteins upregulated in the 2.5 m induced
rTg4510 mouse cortex (Fig. 2a, top panel), with 37% of
heat shock or chaperone proteins showing increased
association with tau with disease (Fig. 2a). This upregu-
lation is consistent with the stress associated with
pre-tangle stage that predominates in the 2.5 m rTg4510
mouse [30]. Interestingly, the third group of proteins
whose association with tau increased in the 2.5 m mice
was nucleotide binding proteins; these include RBPs
such as EWSR1, TAF15 and HNRNPA0, which we pre-
viously reported to co-localize with tau pathology in
the rTg4510 model of tauopathy [37] (Fig. 2a, b). In
addition, aggregation-enhancing mutations in EWSR1
and TAF15 are associated with ALS, suggesting that
changes in the biology of these proteins are sufficient
Fig. 2 RNA binding proteins change in their association to tau in tauopathy. Using Tau13 antibody, tau was immunoprecipitated from the cortex
of either 2.5 month old induced or uninduced rTg4510 brains.The co-immunoprecipitating proteins were subsequently identified by mass
spectrometry. A variety of nucleotide binding and ribonucleoproteins show differential association to tau in rTg4510 tissue compared to WT
tissue as indicated by significantly upregulated and downregulated annotation terms (a). Part (b) represents a network diagram of proteins
enriched in the tau interactome. Red nodes denote proteins whose association with tau is ≥5-fold increased in Tg4510 vs uninduced control.
Blue nodes denote proteins whose association with tau is ≥5-fold decreased in Tg4510 vs control. Node size is proportional to degree of
replication (N = 4), non-replicating proteins excluded. Key proteins include EWSR1, HNRNPA0, PABP, PCBP2, DDX5, TAF15, FMR1, RPL and RPS
family members, and eIF4a2
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to drive neurodegenerative disease [6, 7]. Taken together,
these results highlight that complexes containing tau and
RBPs are a major feature of the pathophysiology of
tauopathy.
RNA binding proteins become insoluble in tauopathy
A key feature of RBP biology is the formation of transient,
dynamic complexes, such as stress granules, P-bodies,
transport granules, and even splicing complexes. With
time or in disease, many RBPs exhibit a tendency to de-
velop into insoluble aggregates. To explore whether RBPs
become insoluble in mouse models of tauopathy, we frac-
tionated frontal cortex from 8 m old rTg4510 mice aged
with low or high levels of human tau (i.e., ± dox). The
samples were then biochemically separated into sarkosyl
soluble or insoluble fractions and immunoblotted. Levels
of RBPs in the sarkosyl soluble group did not change with
disease state (Fig. 3a, b). In contrast, the amount of RBP
present in the insoluble fraction was elevated in diseased
tissues for most of the RBPs examined (Fig. 3a, b). Ana-
lysis of TDP-43 levels showed no change with disease
state, consistent with the lack of association of this protein
with tau aggregation processes. (Fig. 3a, b). These results
suggest that a range of RBPs form insoluble aggregates
with disease in tauopathy.
RNA binding proteins colocalize with phospho-tau but
not mature neurofibrillary tangles in tauopathy
Using immunohistochemistry with confocal micros-
copy, we proceeded to examine how deposition of RBPs
in disease correlated with tau pathology. We examined
proteins identified by mass spectrometry in the tau net-
work (Fig. 2), proteins that we had previously shown to
associate with tau, as well as proteins thought to be in-
volved in the RNA translational stress response and stress
granule formation. Frontal cortex from 6 month old
rTg4510 mice was used for the study because of the pres-
ence of both mature and evolving tau pathology at this
age. Imaging of RBPs using fluorescence immunohisto-
chemistry showed the accumulation of RBPs co-localized
with or near diffuse deposits of phosphorylated tau identi-
fied with CP13, an antibody recognizing pS202 (Fig. 4,
Fig. 3 RNA binding proteins become insoluble in the cortex of rTg4510 mice. (a, b) Immunoblots of the sarkosyl soluble (S3) and insoluble (P3)
fractions isolated from rTg4510 cortical tissues indicate that many RBPs become insoluble as tau pathology develops. The fractions were also
probed for TDP-43, which is not associated with tau aggregation. Quantification of these immunoblots (c, d) shows statistically significant RBP
accumulation in the P3 fraction of induced rTg4510 mouse cortex using a two-tailed t-test (p = 0.00599 for TAOK1; p = 0.0007599 for EWSR1;
p = 0.0122 for TAF15; p = 0.000252 for RPL7; p = 0.00195 for PABP; p = 0.0926 for DDX5; p = 0.0638 for HNRNPA0)
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Additional file 1: Figure S3). The RBPs and proteins linked
to RNA metabolism primarily colocalized with phos-
phorylated tau present in neuronal somas (Fig. 4a); scat-
terplots done on the images demonstrated that when
overlap was present there was strong co-localization with
tau pathology (Fig. 4a, e). We quantified the fraction of
neurons exhibiting CP13 reactivity that also exhibited RBP
reactivity (Fig. 4f, g). Robust correlation for CP13/RBP
co-localization was observed for DDX6, eIF2α, hnRNPA0
and PABP, but not for U2AF2 (Fig. 4f, g); robust
Fig. 4 RNA binding proteins show significant colocalization with diffuse phospho-tau but not NFTs in the rTg4510 cortex. (a) Immunohistochemical
analysis of rTg4510 tissue (n = 3) has also revealed a significant colocalization in the cortex between the RBPs DDX6, PABP, HNRNPA0, and eIF2a (red)
with pathological phospho-tau stained using the CP13 antibody (green). However, the RBP and splicing factor U2AF2 does not show significant
correlation. To the right of each merged image is a scatterplot of the pixel intensities for each pixel of the image in the red channel vs. the green
(Pearson correlation coefficients r = 0.773 for DDX6, 0.791 for eIF2α, 0.325 for HNRNPA0, 0.798 for PABP, and− 0.14 for U2AF2). This colocalization is
greatly reduced and/or completely lost as tau aggregates into large NFTs which are brightly fluorescent and fill the cell bodies of neurons (b)
(r = 0.069 for DDX6, 0.372 for eIF2α, 0.481 for PABP, − 0.03 for HNRNPA0, and − 0.009 for U2AF2). c Staining of wild-type C57Bl/6 mice also indicates
that HNRNPA0 is predominantly nuclear in healthy animals, while the rTg4510 staining shows significant cytoplasmic localization of HNRNPA0 (a, b).
(d) Negative controls IHC using rabbit and mouse normal IgG indicates that there is no off target staining or fluorescence in our tissues. e Pearson
coefficients of correlation between CP13 positive tau with RBPs DDX6, eIF2α, HNRNPA0, PABP, and U2AF2 are graphed for individual neurons using
ImageJ. For all cases except U2AF2, neurons show heterogeneity in colocalization between phospho-tau and the RBPs stained, from no colocalization
to fully overlapping reactivity patterns in individual neurons. The percent of neurons with r > 0.3 is graphed in (f) as the percentage of neurons
showing moderate to strong correlations between green:red intensity (DDX6 = 36% of neurons; eIF2α = 54% of neurons; HNRNPA0 = 35% of neurons;
PABP = 33% of neurons; U2AF2 = 0% of neurons)
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correlation was also observed for TIA1 (Fig. 1f). Interest-
ingly, little colocalization was observed with mature NFTs
showing bright condensed CP13 reactivity (Fig. 4b), con-
sistent with the studies of TIA1 in Fig. 1e, f. Some of the
RBPs (e.g., DDX6 and hnRNPA0) appear to remain as
aggregates but accumulate adjacent to the tau NFTs, as if
the RBPs are excluded from large, consolidated tau tan-
gles, and pushed to the periphery of such tangles (Fig. 4b).
Finally, we examined the pattern of reactivity of RBPs
in human tissue. We examined temporal cortex of late
Braak stage V and VI human AD patients (Fig. 5). At this
stage of disease, CP13 positive phospho-tau exists pre-
dominantly as NFTs (showing bright condensed CP13
reactivity), with little diffuse phospho-tau, such as is seen
at 6–8 months of age in the rTg4510 mouse model (Fig.
S6). RBP inclusions were readily apparent in the human
tissues using antibodies against DDX6 and hnRNPA0
(Fig. 5). Comparison of the distribution of the RBP and
tau deposits in individual neurons suggests an inverse
correlation between RBP localization and mature NFTs
similar to that observed in the rTg4510 mouse tissue
(Fig. 5, intensity plots). In addition, we observed that
some RBPs (e.g., DDX6 and hnRNP0) accumulated as
pathological inclusions, but accumulated adjacent to the
mature tangles, much like what was observed in
rTg4510 mice (Fig. 5). These results demonstrate that
deposits of RBPs occur near deposits of pathological tau,
but suggest that RBPs are excluded from the aggregated
tau as the deposits consolidate.
Discussion
Characterization of the tau interactome in the rTg4510
mouse model of tauopathy reveals striking disease-related
changes in interactions between tau and multiple RBPs.
About 65% of proteins in the RBP group show decreased
tau association with disease. A smaller number of RBPs
increase the association of tau with disease, including
EWSR1, TAF15 and hnRNPA0, each of which have been
linked to ALS (e.g., EWSR1 or TAF15) or have related
family members linked to ALS (hnRNPA0 shares hom-
ology with hnRNPA2B1). Formation of aggregates was
evident biochemically and by immuhistochemisty which is
Fig. 5 RBPs show granularization and interfacing with NFTs in late stage human AD tissue. Immunohistochemical analysis of human AD frontal
cortex tissue (n = 6) shows that RBPs (red) and NFTs stained with CP13 tau (green) do not colocalize (r = 0.001 for DDX6; 0.176 for eIF2α; 0.031 for
HNRNPA0; and 0.222 for PABP). However, trace analyses across lines within the image (yellow bars) indicate that peak fluorescent intensities
(reported as fluorescence intensity plots over the distance of the line for tau in green and the RBP in red) between phospho-tau and multiple
RBPs are immediately adjacent to each other, indicating protein interfacing or interaction between the edges of NFTs and RBPs
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consistent with prior studies showing multiple U1 spliceo-
some components that accumulate in the sarkosyl-insoluble
fraction of AD tissues [2].
Imaging studies suggest that the pattern of
co-localization varied depending on the type of RBP,
and the size of the inclusion. For the RBPs examined in this
manuscript, TIA1 showed the strongest co-localization with
tau pathology. Co-localization for TIA1 with tau could be
observed for phospho-tau (CP12, p-S202) and oligomeric
tau (TOC1). Other RBPs, including hnRNPA0, DDX6,
eIF2α and (to a lesser extent) PABP also co-localized with
phospho-tau pathology. Direct co-localization was observed
with small tau puncta, but for large tau inclusions these
RBPs tended to accumulate immediately adjacent to the in-
clusion. The observation of RBP inclusions adjacent to tau
tangles has also been observed for small nuclear ribonuc-
lear proteins, such as U2AF2 [12, 13]. The differential
localization of RBP inclusion with tau aggregate size sug-
gests a model in which these proteins initially co-localize
with tau but become excluded as the tau aggregates
consolidate into mature neurofibrillary tangles. This work
adds key information to our prior data indicating that
phospho-tau (specifically, tau phosphorylated at the classic
proline directed serine/threonine sites associated with path-
ology) promotes SG formation [37].
These results suggest the hypothesis that tau and RBPs
exhibit progressive maturation (Fig. 6). This process ap-
pears to begin with a stress response that includes the
translational stress response, which leads to cytoplasmic
translocation of nuclear RBPs (Fig. 6a), followed by for-
mation of functional SGs in part through interaction
with phosphorylated, oligomeric tau (Fig. 6b) [1, 37].
The association of tau with SGs also produces aggrega-
tion, much as occurs with disease-prone RBPs during
extended or repetitive periods of liquid liquid phase
separation (LLPS) [22, 27, 28, 37]. Tau also undergoes
LLPS, and does so in a manner that is accelerated by the
presence of mRNA [14, 39, 42]. The similar biophysical
behavior of tau and RBPs, the association of tau with
SGs, the ability of tau to promote SG formation, and the
tendency of tau to aggregate in the presence of SGs,
provide a strong basis for a model based on the inter-
action of tau with SGs. Co-localization of tau with
SG-associated RBPs suggest that the tau complexes with
RBPs complexes that either are SGs or resemble SGs,
which then mature during chronic stress into persistent
Fig. 6 Model for the evolution of tau pathology a Stress elicits translocation of nuclear RBPs, such as TIA1 and HNRNPA0, to the cytoplasm where
they distribute diffusely in the cytoplasm. b Core nucleating RBPs, such as TIA1, coalesce to form SGs, in a process that is stimulated by tau
oligomers. Secondary nucleation brings in other RBPs, such as EWSR1, PABP, DDX6, EIFs, etc. c Persistent stress (such as occurs in disease) causes
particularly insoluble RBPs (and tau) to consolidate to form persistent pathological stress granules. More soluble RBPs separate from the persistent
pathological SG, and disperse without aggregating. d The tau oligomers evolve into fibrils forming pathological puncta, which contain classic
markers of pathology such as hyper-phosphorylation and ubiquitination [43]. Other RBPs that remain associated with the persistent pathological
SG, begin to form aggregated puncta around the tau puncta. e Tau fibrillizes forming neurofibrillary tangles, which are relatively inert, do not act
in the translational stress response and contain few RBSs
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pathological SGs (Fig. 6c). Based on our data, we
hypothesize that persistent SGs lose many types of RBPs
and perhaps reducing their physiological activity (Fig. 6d);
ubiquitin is added into the model at this point to reflect
the well-documented association of ubiquitin with mature
tangle pathology [43]. As the aggregated tau in these
pathological SGs consolidates they appear to exclude
many RBPs, and ultimately become the inert pathological
structures that are referred to as neurofibrillary tangles
(Fig. 6e). Meanwhile, the excluded RBPs form inclusions
that accumulate adjacent to the neurofibrillary tangles.
The latter stages of this hypothesis (steps 6c - e) remain to
be explicitly tested beyond the correlative evidence pre-
sented above, but the model sets up a paradigm to guide
future studies.
This model is further supported by accumulating evi-
dence pointing to a persistent translational stress response
as a key pathway leading to the accumulation of SGs.
Chronic disease could produce a chronic stress, which
leads to persistence of SGs. The high concentration of
RBPs in SGs (100–400-fold higher than dispersed RBP
levels) creates conditions that also promote aggregation of
RBPs into insoluble amyloids, which over time accumulate
[16, 24, 31]. Support for the persistent SG hypothesis
comes from protection experiments in cell culture and in
transgenic models. Bonini and colleagues demonstrated
that chemical inhibition of the SG pathway rescues the
ALS phenotype in drosophila [20]. Ataxin-2 deletion,
which also inhibits the SG/translational stress response
pathway, also delayed disease progression in a mouse
model of ALS [3]. The relevance of the SG pathway to
tauopathy was recently demonstrated by our observation
that TIA1 reduction protects against disease progression
in a mouse model of tauopathy [1]. Studies using primary
neurons support these results by demonstrating that both
RNAi knockdown of TIA1 and chemical inhibition of the
SG pathway are able to prevent tau-mediated toxicity [37].
Thus, multiple independent lines of evidence demonstrate
that RBPs, SGs and the translational stress response con-
tribute to the pathophysiology of tauopathy and other
neurodegenerative diseases.
The putative role for tau in regulating the RNA metab-
olism is supported by proteomic studies of tau interac-
tomes from multiple different groups, which also identify
similar classes of proteins that associate with tau. Immu-
noprecipitation and mass spectrometry of tau (both WT
and P301L) binding proteins from SH-SY5Y neuroblast-
oma cells showed strong overlap of RBPs and ribosomal
protein with the proteins identified in our study, including
EWSR1, DDX5 & 17, hnRNPK, L, R and U, as well as
ribosomal proteins RPL7, 8, 27 and 30 [10]. Proteomic
studies of complexes containing tau from the rTg4510
mouse model and human AD tissues also report RNA
binding and nucleotide binding proteins in their results,
as well as multiple heat shock proteins and chaperones
[4, 25]; work from the Abrisambra laboratory also dir-
ectly demonstrates that tau over-expression inhibits
RNA translation [25, 26]. Studies using HeLa cells re-
port multiple RBPs in the tau interactome, including
TIA1, hnRNP family members, and many ribosomal
subunit proteins, and also demonstrated the presence
of aggregated RBPs in the AD brain [36]. A recent
study of tau-associated proteins in lymphoblastoid cell
lines containing AKAP9 mutations linked to AD show
enrichment of RNA binding and spliceosomal proteins
in the tau proteome [17]. These proteins again include
EWSR1, TAF15, DDX family members, and RPL family
members, which parallels our findings. Finally, our own
work previously demonstrated the association of TIA1
with tau by both proteomic analysis as well as immuno-
precipitation [37]. These data demonstrate that identifi-
cation of complexes containing tau and RBPs is a
reproducible observation. The nature of the tau species
responsible for binding to each RBP remains to be de-
termined, and might differ between tau monomers,
oligomers and fibrils; for instance, our recent study
suggest that TIA1 exhibits preference for tau oligomers
[1]. The studies also provide strong support for an
emerging consensus that tau functions in stress to
regulate the translation stress response through inter-
action with RBPs and SGs.
Our current study combines with accumulating prior
studies to suggest that tauopathies (including AD) exist
in the spectrum of neurodegenerative diseases and my-
opathies that are associated with dysfunction of RBPs,
which already includes ALS and FTD. The current work
advances the field by identifying a number of RBPs that
can be reliably associated by immunohistochemistry with
tau pathology, and providing optimized methods for
detecting the association. These advances will facilitate
rigor and reproducibility for this emerging field. Finally,
the consistent role of RBPs and SGs in the mechanisms
of multiple neurodegenerative diseases suggests that dys-
function of RBPs, SGs and translational stress response
pathways plays a fundamental role in the pathophysiology
of neurodegenerative diseases, and that seemingly dispar-
ate diseases might converge on common downstream
mechanisms for neurodegeneration.
Materials and Methods
Animal husbandry and tissue collection
Animal husbandry for the rTg4510, PS19 and TIA1−/−
mice was approved and performed as previously described
in each indicated reference. For all brain harvesting, mice
were anesthetized in an isoflurane chamber and perfused
with ice cold PBS. Brains were then harvested and proc-
essed according to each subsequent experiment recorded
below.
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Human brain samples
Temporal cortex tissue from human brain was used for
the immunohistochemical studies. The samples were
de-identified. The cases are listed in Table 1 below:
Immunohistochemistry and quantification
All mouse (n = 8 rTg4510 and n = 8 wild type C57BL6/J)
and human (n = 7 AD cases and n = 8 aged control) tis-
sue was sectioned at 20um on a cryostat and stained as
free floating sections using Netwell baskets (VWR
Cat#29442–132) in 12 well Falcon plates (Cat#353043).
Extracted mouse tissues were drop fixed in15mL 4%
PFA for 24 h, transferred to 15 mL 30% sucrose in PBS
for 48 h, then sectioned and stored in cryoprotectant
(30% ethylene glycol; 30% glycerol; 40% PBS) at − 20 °C.
We note that a recent study of stress granule pathology
showed excellent labeling of TIA1 and other RBPs in a
mouse model of tauopathy using perfusion with cold
paraformaldehyde (4%), followed by drop fixation in cold
paraformaldehyde for 2 h, transfer to 30% sucrose in
PBS for at least 48 h [33]. Human tissues were fixed and
stored in periodate-lysine-paraformaldehyde (PLP) until
sectioned using a Leica VT1200S vibratome. To quench
lipofuscin autofluorescence, sections were photobleached
under a 1500 lm white LED bulb for a minimum of 72 h
at 4 °C while suspended in PBS with no lid or covering
[34]. Note that the photobleaching is time-limited; sec-
tions examined were observed to recover lipofuscin au-
tofluorescence after approximately 1 week following the
photobleaching. Sections were then washed 3× in PBS
for 30 s each wash followed by a 5-min incubation in
detergent media (TBS with 0.25% Triton-X). Human
tissue, but not mouse tissue, was then incubated in
1%w/v sodium borohydride (NaBH4; Sigma-Aldrich
Cat#452882-25G) in PBS for 45 min to quench aldehyde
autofluorescence which results from the over-fixation of
tissue. All tissue was then incubated for 1 h in citrate
based antigen unmasking solution (Vector Cat#H-3300)
at 95 °C, with the exception of human TIA1 staining
(Fig. 1), which was done using 0.05% citraconic anhydride
(Sigma-Aldrich Cat#125318-25G) for 1 h at 95 °C. Tissue
was blocked with gentle rotating for 2 h in detergent
media with 5% donkey serum (Sigma-Aldrich
D9663-10 mL) in PBS. After blocking, tissue was washed
once in PBS for 30 s to remove excess detergent, then
moved into 24 well plates with 200uL of the appropriate
primary antibody dilutions and no basket overnight at 4 °
C. To prevent evaporation, the lids of each plate were
lined with a damp Kimwipe. Antibody catalog numbers
and dilutions are recorded in Additional file 3: Table S2.
Following primary antibody incubation, tissue sections
were washed 4× in PBS using baskets in 12 well plates
for 5-min each wash. Tissues were then incubated in
200uL of secondary antibody solution containing a 1:500
dilution of the appropriate secondary antibody (Jackson
Immunoresearch Alexafluor-488 and 549 secondaries)
for 1.5 h in the dark at room temperature. If needed,
after 1.5 h 300uL of a 1μg/mL DAPI solution was added
to each tissue and incubated in the dark for 5 min at
room temperature. Tissues were then washed 4× in PBS
for 5 min each and carefully placed on Millenia 2.0 slides
(StatLab Medical Products Cat#318) using a histology
brush (Fisher Scientific Cat#NC0344756). Excess water
was allowed to evaporate for 15 min, then each slide was
mounted with 100uL of Prolong Gold Antifade Reagent
(Thermo Fisher Cat#P36930) and a 1 mm cover slip.
All imaging was done using a Zeiss LSM 700 confocal
microscope at either 40× or 63× magnification with a
1 AU pinhole. Following imaging, images were processed
using either Imaris BitPlane software or the Fiji distribu-
tion of ImageJ. An Imaris BitPlane surfaces algorithm
(Bitplane AG, Zurich, Switzerland) was used to quantify
the tangle size vs. TIA1 intensity recorded in Fig. 1. The
Coloc2 plugin of Fiji was used to determine colocaliza-
tion parameters recorded in Fig. 4 following background
subtraction with a rolling ball radius of 50. Intensity
plots for Figs. 4 and 5 were also measured and generated
using ImageJ-Fiji; regions of interest were set across a
line using the line tool, and then measured using
analyze- > plot profile.
Tau immunoprecipitation for mass spectrometry analysis
2.5 mo rTg4510 and uninduced transgenic mouse brains
(n = 4/group) were extracted, slowly frozen by submer-
sion in methanol on dry ice, and homogenized in RIPA
lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton
X-100, 0.1% SDS, 0.5% sodium deoxycholate, pH 6.8)
Table 1 AD cases used for immunohistochemical studies
Age Gender Braak Stage
74 M V
96 M V
57 F VI
80 F VI
97 F V
87 F VI
87 F II
67 F II
84 F I
70 M I
90 F II
93 F II
91 M II
79 M VI
95 M II
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supplemented with protease (Roche Cat#04693159001)
and phosphatase inhibitor (Roche Cat#04906837001)
cocktails. Tau was immunoprecipitated from 1 mg
cortex lysate using 10 μg of the mouse monoclonal
Tau13 antibody immobilized on Pierce Direct IP col-
umns according to manufacturer’s instructions (Thermo
Scientific, Cat#26148). The Tau13 IP eluates were then
separated on a Novex 4–12% Bis-Tris polyacrylamide gel
(Life Technologies, Cat#NP0323) and stained with Sim-
ply Blue Coomassie G-250 SafeStain (Life Technologies,
Cat#LC6060). Whole gel lanes were then excised and
shipped to the UMass Mass Spectrometry and Proteo-
mics facility for analysis by LC-MS/MS.
Proteomics, in gel digestion
Gel slices were cut into 1 × 1 mm pieces and placed in
1.5 ml eppendorf tubes with 1 ml of water for 30 min.
The water was removed and 50ul of 250 mM ammo-
nium bicarbonate was added. For reduction 20 μl of a
45 mM solution of 1, 4 dithiothreitol (DTT) was added
and the samples were incubated at 50 C for 30 min. The
samples were cooled to room temperature and then for
alkylation 20 μl of a 100 mM iodoacetamide solution
was added and allowed to react for 30 min. The gel
slices were washed 2 X with 1 ml water aliquots. The
water was removed and 1 ml of 50:50 (50 mM Ammo-
nium Bicarbonate: Acetonitrile) was placed in each tube
and samples were incubated at room temperature for
1 h. The solution was then removed and 200 ul of aceto-
nitrile was added to each tube at which point the gels
slices turned opaque white. The acetonitrile was re-
moved and gel slices were further dried in a Speed Vac.
Gel slices were rehydrated in 75 μl of 2 ng/μl trypsin
(Sigma) in 0.01% ProteaseMAX Surfactant (Promega):
50 mM Ammonium Bicarbonate. Additional bicarbonate
buffer was added to ensure complete submersion of the
gel slices. Samples were incubated at 37C for 21 h. The
supernatant of each sample was then removed and
placed in a separate 1.5 ml eppendorf tube. Gel slices
were further dehydrated with 100 ul of 80:20 (Aceto-
nitrile: 1% formic acid). The extract was combined with
the supernatants of each sample. The samples were then
dried down in a Speed Vac. Samples were dissolved in
25 μl of 5% Acetonitrile in 0.1% trifluroacetic acid prior
to injection on LC/MS/MS.
LC/MS/MS on Q Exactive
A 3.0 μl aliquot was directly injected onto a custom
packed 2 cm × 100 μm C18 Magic 5 μm particle trap
column. Labeled peptides were then eluted and sprayed
from a custom packed emitter (75 μm× 25 cm C18
Magic 3 μm particle) with a linear gradient from 95%
solvent A (0.1% formic acid in water) to 35% solvent B
(0.1% formic acid in Acetonitrile) in 90 min at a flow
rate of 300 nanoliters per minute on a Waters Nano
Acquity UPLC system. Data dependent acquisitions were
performed on a Q Exactive mass spectrometer (Thermo
Scientific) according to an experiment where full MS
scans from 300 to 1750 m/z were acquired at a reso-
lution of 70,000 followed by 10 MS/MS scans acquired
under HCD fragmentation at a resolution of 17,500 with
an isolation width of 1.6 Da. Raw data files were proc-
essed with Proteome Discoverer (version 1.4) prior to
searching with Mascot Server (version 2.5) against the
Uniprot database. Search parameters utilized were fully
tryptic with 2 missed cleavages, parent mass tolerances
of 10 ppm and fragment mass tolerances of 0.05 Da. A
fixed modification of carbamidomethyl cysteine and
variable modifications of acetyl (protein N-term), pyro
glutamic for N-term glutamine, oxidation of methionine
were considered. Search results were loaded into the
Scaffold Viewer (Proteome Software, Inc.).
Proteomic analysis
Quantitative proteomic analysis was performed using
the total ion current (TIC) for proteins identified by
LC-MS/MS normalized to the TIC level of TIA1 de-
tected in each sample. Proteins identified in the TIA1
−/− samples were considered to be nonspecific binding
proteins to the IP antibody and excluded from all subse-
quent analyses. Gene lists of detected proteins were then
uploaded into the Database for Annotation, Visualization
and Integrated Discovery (DAVID) resource available via
the NIH website.
The proteins identified in the tau binding proteome in
WT C57BL/6 J cortex resulted in 6 identified clusters with
enrichment FDR < 0.05, and each of the proteins was asso-
ciated to the cluster(s) based on its membership in the
clustered gene sets. A network was created by adding a
connection between protein pairs sharing annotation clus-
ters. Edge weights were determined as the number of
shared annotation clusters between protein pairs with
thicker edges representing stronger functional associations
between proteins (the smallest number of clusters shared
between any two proteins was 1, and the largest was 8).
The resulting network was visualized using the software
Gephi 0.8.2 and arranged using the Force Atlas 2 layout
algorithm. The network was generated using the python
programming language (Python Software Foundation),
and the networkx, numpy, and pandas python packages.
CoIP validation of mass spectrometry
Brains from 6 month old PS19 mice expressing P301S tau
were extracted and freshly homogenized using 400uL IP
lysis buffer (0.025 M Tris; 0.15 M NaCl; 0.001 M EDTA;
1% NP-40, 5% glycerol; pH 7.4) supplemented with prote-
ase inhibitor cocktail (Roche Cat#04693159001), phos-
phatase inhibitor cocktail (Roche Cat#04906837001),
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and 20 units RNase inhibitor (ThermoFisher Scientific
#AM2964). 1 mg of each lysate was pre-cleared with
80uL Protein G Dynabeads, and 50uL of Protein G
Dynabeads (Invitrogen #10004D) per lysate were pre-
pared with either 10μg Tau13 according to manufac-
turer instructions. Lysates and beads were equivalently
pre-cleared and prepared with 10μg normal mouse IgG.
Pre-cleared lysates were immunoprecipitated with the
antibody conjugated beads using gentle rotation over-
night at 4 °C; protein was eluted by boiling in Bolt
SDS-PAGE sample buffer for 10 min and analyzed
using SDS-PAGE. Antibodies used in the western blot
analysis are recorded in supplemental Table 2.
Sarkosyl fractionation and immunoblotting
Extracted brain tissue from (n = 3) rTg4510 and (n = 3)
uninduced Tg4510 control mice was weighed and placed
in a Beckman centrifuge tube, polycarbonate thick wall
(Cat#362305). Tissue was homogenized in 4× weight/
volume of homogenization buffer (50 mM Tris; 275 mM
NaCl; 5 mM KCl; 1 mM PMSF; pH = 8.0 with protease
inhibitors, phosphatase inhibitors and PMSF added im-
mediately before use) and ultracentrifuged at 28 k rpm
(29,800 g) in a TLA-55 rotor for 20 min at 4 °C using a
Beckman Optima-TLX 120,000 ultracentrifuge. The
supernatant was removed and stored at − 80 °C as the
TBS soluble supernatant (supernatant S1); excess super-
natant was then vacuumed off the pellet, and the pellet
was suspended in sucrose buffer (10 mM Tris, pH = 7.4;
0.8 M NaCl; 10% sucrose; 1 mM EGTA; 1 mM PMSF).
The suspension was ultracentrifuged at 22 k rpm
(26,300 g) for 20 min at 4 °C. 450uL of the supernatant
was transferred to a new tube with the pellet stored at −
80 °C (pellet P2). This supernatant was incubated with 1%
Sarkosyl for 5 min with gentle rotation at room
temperature then 1 h at 37 °C. After Sarkosyl incubation
the solutions were ultracentrifuged at 55 k rpm
(150,000 g) for 1 h at 4 °C. The supernatant was stored at
− 80 °C (supernatant S3) and the pellet was resuspended
in 60uL TE buffer (10 mM Tris, pH = 8.0, 1 mM EDTA)
and also kept at − 80 °C as the P3 pellet.
The Sarkosyl soluble S3 supernatant and insoluble P3
pellet were analyzed for RBP content using SDS-PAGE
and immunoblotting. As the protein concentration of all
tissues were normalized at the start of fractionation,
20uL of the P3 pellet and 5uL of the S3 supernatant
were run on a Bolt 4–12% Bis-Tris Plus polyacrylamide
gel (Life Technologies Cat#NW04127BOX) at 120 V for
1 h and 15 min. Proteins were transferred onto nitrocel-
lulose at 12 V for 1 h, and membranes were blocked in
Tris-buffered saline (24 g Tris base; 88 g NaCl; 1 L
water; pH = 7.6) with 0.1% Tween (TBS-T); with 5%
non-fat milk for 2 h. After blocking membranes were in-
cubated with 10 mL of the appropriate primary antibody
in TBS-T overnight at 4 °C; primary antibodies and dilu-
tions are recorded in supplementary Table 2. Mem-
branes were washed 4× for 5 min each was in TBS-T,
then incubated with the appropriate HRP-conjugated
secondary antibody at a 1:15,000 dilution in TBS-T
(Jackson Immunoresearch) for 1.5 h. Membranes were
again washed 4× for 5 min each in TBS-T then devel-
oped using Pierce SuperSignal West Pico Chemilumines-
cent Substrate (Thermo Fisher Scientific Cat#34080).
Blots were quantified using ImageJ peak analysis.
Additional files
Additional file 1: Figure S1. TIA1 antibodies demonstrate significant
variability. Four commercial TIA1 antibodies were screened for performance
in fluorescent immunohistochemical assays: Abcam 40,693 (A), Santa Cruz
1751 (B), Abcam 140,595 (C), and Cell Signaling 1398S (D). Of these, only
Abcam 40,693 demonstrated affinity for both cytoplasmic and nuclear TIA1
with minimal background reactivity, but also shows performance variability
between lots (E). Figure S2. Co-immunoprecipitation (co-IP) and immuno-
blotting (IB) of tau and RBPs from the brains of P301S tau mice (n = 2).
HNRNPA0 (35kD), eIF4a2 (47kD), HNRNPK (55kd), and RPL11 (23kD) co-IPd
with Tau13 (left) but not normal mouse IgG (right). Figure S3. Immunhisto-
chemical analysis of rTg4510 tissue (n = 3) revealed a significant co-
localization in the cortex between the PCBP2 (r = 0.724), RPL11 (r = 0.728),
and eIF3h (r = 0.315) (red) with pathological phospho-tau stained with CP13
antibody (green). Figure S4. Duration of fixation affects sensitivity of RBP
detection. Samples were fixed for 24 h (top row) or 48 h (bottom row) with
4%, and imaged for NeuN or TIA1; DAPI identifies nuclei. Figure S5. Photo-
bleaching of tissue removes autofluorescence from lipofuscin and the extra-
cellular matrix. Human AD tissue was treated with white light from an LED
bulb for 72 h and then imaged. Untreated tissue shows significant auto-
fluoresence in the red and green channels (top), which was removed with
photobleaching (bottom). Figure S6. Consolidated but not diffuse
phospho-tau is present in late stage tissue. Tangle morphology and intensity
were compared in 6-month rTg4510 mouse tissue (left) and human
AD tissue (right). In the human tissue, CP13 positive tau presents
entirely as consolidated NFTs, which extend into the processes. The
mouse tissue showed a continuum of pathological tau including
diffuse cytoplasmic phospho-tau (white arrows), CP13 positive puncta,
and intense, consolidated NFTs. (PDF 956 kb)
Additional file 2: Table S1. Mass spectometry data. This table provides
quantification of the proteins identified by mass spectrometry, and shows
# peptides identified, fold changes and P-values for each protein
identified. (XLSX 65 kb)
Additional file 3: Table S2. List of antibodies used in the study. This
table provides source information for each antibody, as well as the
diltuion at which each antibody was used in the experiments. (XLSX 9 kb)
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